A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis

NCT07532486 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Guselkumab
DRUG: Guselkumab

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University